Form 4 Filing for Acrivon Therapeutics, Inc.

Ivana Magovcevic-Liebisch, a director at Acrivon Therapeutics, Inc., acquired 9,366 shares of common stock on May 18, 2026. This transaction was made under a restricted stock unit (RSU) award, which is set to vest in full on May 18, 2027, contingent upon her continued service. The acquisition was reported with a transaction price of $0.00 per share, indicating it was part of a stock-based compensation plan. Following this transaction, Magovcevic-Liebisch holds 9,366 shares directly. The filing also notes that these RSUs represent a contingent right to receive one share of the Issuer's Common Stock upon vesting.